



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CP21R7

Cat. No.:	HY-100207		
CAS No.:	125314-13-8		
Molecular Formula:	C ₁₉ H ₁₅ N ₃ O ₂		
Molecular Weight:	317.34		
Target:	GSK-3		
Pathway:	PI3K/Akt/mTOR; Stem Cell/Wnt		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 32 mg/mL (100.84 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.1512 mL	15.7560 mL	31.5119 mL
	5 mM		0.6302 mL	3.1512 mL	6.3024 mL
	10 mM		0.3151 mL	1.5756 mL	3.1512 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (7.88 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	CP21R7 is potent GSK-3β inhibitor, with an IC ₅₀ of 1.8 nM; CP21R7 also shows inhibitory activity against PKCα, with an IC ₅₀ of 1900 nM.	
IC ₅₀ & Target	GSK-3β 1.8 nM (IC ₅₀)	PKCα 1900 nM (IC ₅₀)
In Vitro	CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC ₅₀ of 1.8 nM; the IC ₅₀ of CP21R7 against PKCα is 1900 nM ^[1] . CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

CUSTOMER VALIDATION

- Small. 2023 Jan 12;e2207194.
- J Mol Cell Cardiol. 2023 Jan 16;176:21-32.
- J Mol Cell Cardiol. 2021 Oct 16;S0022-2828(21)00197-8.
- STAR Protoc. 2022 Apr 13;3(2):101296.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Gong L, et al. Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6.
- [2]. Patsch C, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015 Aug;17(8):994-1003.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA